Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft
Launched by BIOMIMETIC THERAPEUTICS · Aug 22, 2016
Trial Information
Current as of June 24, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Subjects who meet the following criteria may be included in the study:
- • 1. Must be willing and able to provide informed consent and be available for the planned follow-up evaluations and radiologic tests; and
- • 2. Must have been randomized, treated and included in the safety population of Protocol BMTI-2006-01 (see Exhibit 13.1).
- Exclusion Criteria:
- • 1) Subjects that were excluded from the safety analysis in the BMTI-2006-01 study (subjects not listed in Exhibit 13.1). These subjects were consented, but never treated as part of the BMTI-2006-01 protocol.
About Biomimetic Therapeutics
Biomimetic Therapeutics is a pioneering clinical trial sponsor dedicated to advancing innovative treatment solutions by leveraging nature-inspired technologies. With a focus on developing biomimetic therapies, the company aims to enhance patient outcomes through targeted, effective, and safe medical interventions. Committed to rigorous scientific research and ethical practices, Biomimetic Therapeutics collaborates with leading researchers and institutions to drive the translation of groundbreaking discoveries into clinical applications, ultimately striving to improve healthcare and quality of life for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Rochester, New York, United States
Cleveland, Ohio, United States
Hartford, Connecticut, United States
Toronto, Ontario, Canada
San Francisco, California, United States
Tucson, Arizona, United States
Philadelphia, Pennsylvania, United States
Toronto, Ontario, Canada
Germantown, Tennessee, United States
Charlotte, North Carolina, United States
Grand Rapids, Michigan, United States
Bend, Oregon, United States
Newark, New Jersey, United States
Capitola, California, United States
Royal Palm Beach, Florida, United States
Glenview, Illinois, United States
Baltimore, Maryland, United States
Lansing, Michigan, United States
Las Vegas, Nevada, United States
Durham, North Carolina, United States
Westerville, Ohio, United States
Falls Church, Virginia, United States
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Halifax, Nova Scotia, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials